Premature Ovarian Insufficiency
Conditions
Brief summary
This study was a single-center, randomized, controlled prospective study. Those who had premature ovarian failure and who had fertility requirements were enrolled in the study. To determine the efficacy and safety of umbilical cord mesenchymal stem cells in the treatment of patients with POI.
Detailed description
According to the enrollment and exclusion criteria, the patients were enrolled, and the subjects were randomly divided into two groups by computer randomization. Group A was hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells (test group). Group B was the hormone replacement group (control group).
Interventions
PROCEDUREtransplantation of human UC-MSCs into ovaries of POI patients
UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
DRUGhormone replacement treatment
Routine estrogen progesterone replacement periodic therapy
Sponsors
Li-jun Ding
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 39 Years
Healthy volunteers
No
Inclusion criteria
1. Those who meet the POF diagnostic criteria and have no spontaneous follicular activity; 2. Married, 20 years old ≤ age \< 40 years old; 3. The average diameter of each ovary is \> 10 mm; 4. Have agreed to sign the informed consent form.
Exclusion criteria
1. Female and/or male chromosomal abnormalities; 2. Endometriosis, adenomyosis; 3. Postoperative ovarian borderline or malignant tumor; 4. Uterine dysplasia; 5. Associated with female autoimmune disease or other serious internal surgical diseases; 6. hormone replacement contraindications; 7. In the past 1 year, had received an experimental study of premature ovarian failure in the external hospital; 8. Male azoospermia or severe oligozoospermia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Follicular development rate | 9-12 months | Follicular development and hormonal examination were performed 1 week before treatment and at 1, 2, and 3 weeks after treatment to evaluate the development of follicles. If there is no follicular development in the third week, stop the drug after 1 week, and contact the next treatment time after menstruation. During the follow-up period to half a year after the end of the last treatment, the follicular development activity rate was observed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in blood flow index in the ovary | 9-12 months | Ovarian artery blood flow spectrum PI; RI; S/D (L; R) |
| Clinical pregnancy rate | 9-12 months | Clinical pregnancy was defined as diagnosed by increasing serum concentration of beta-HCG 14 days after embryo transfer, and the subsequent demonstration of an intrauterine gestational sac by ultrasonography on 30 days after embryo transfer |
Countries
China
Contacts
Primary ContactHaixiang Sun, phD
Backup ContactLijun Ding, phD
Outcome results
None listed